Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Integra LifeSciences (NASDAQ:IART) announced the acquisition of Surgical Innovation Associates (SIA) for $50 million, with potential additional payments totaling $90 million based on performance metrics. This strategic acquisition enhances Integra's product offerings in plastic and reconstructive surgery, particularly in breast reconstruction, addressing a growing market opportunity. The FDA is currently reviewing Integra's pre-market approval application for its existing SurgiMend product, and the transaction is expected to be dilutive to earnings in year one but accretive by year three.

Integra LifeSciences (Nasdaq: IART) has reached a definitive agreement to acquire Surgical Innovation Associates (SIA) for up to $140 million. The transaction includes $50 million at closing and an additional $90 million contingent upon achieving specified milestones. SIA's DuraSorb® technology, which has seen 80-100% annual revenue growth, will enhance Integra's surgical portfolio and expedite market entry for plastic and reconstructive surgical devices. Closing is expected by year-end, pending customary conditions.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported Q3 2022 revenues of $385 million, a decrease of 0.4% year-over-year, with a 3.5% increase on an organic basis. GAAP earnings per diluted share rose to $0.60, compared to $0.51 last year. The company raised its EPS outlook to $3.29-$3.33 and reaffirmed revenue guidance between $1,551-$1,563 million, indicating organic growth of 3.7%-4.5%. The TWC business was sold for $28.8 million, and cash flow from operations reached $68 million. Full-year guidance reflects adjustments due to foreign currency impacts.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) plans to release its third quarter 2022 financial results on October 26, 2022, before market opening. This will be followed by a conference call hosted by the management team at 8:30 a.m. ET. Investors can access the call by dialing 866-571-0905 with passcode 1121226# or through a live webcast on the company’s website. A replay will be available until November 7, 2022.

Integra LifeSciences (NASDAQ: IART) announced the appointment of Harvinder Singh as executive vice president and president of its international business. Singh brings over 20 years of experience from Abbott Laboratories, where he held various senior roles, including vice president of global commercial operations in the vascular sector. His expertise is expected to support Integra's growth strategy in international markets. Singh holds degrees in chemistry and biology from Punjab University and an MBA from the University of Indore, along with completing the Harvard Business School’s Advanced Management Program.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in two upcoming investor conferences. CEO Jan De Witte will present at the Wells Fargo 2022 Healthcare Conference in Boston on September 7, 2022, at 8:35 am ET. CFO Carrie Anderson will speak at the Morgan Stanley Annual Global Healthcare Conference in New York on September 12, 2022, at 11:05 am ET. Interested parties can find webcast information on the Company’s website.

Integra LifeSciences (NASDAQ:IART) announced the passing of Dr. Richard Caruso, founder and former chairman and CEO, on August 14, 2022. Dr. Caruso's vision revolutionized the field of regenerative medicine, leading to groundbreaking products like the Integra Dermal Regeneration Template approved by the FDA in 1996. His leadership from 1992 to 2011 established Integra as a global leader in regenerative tissue technologies. The company continues to improve patient care through its diverse portfolio, enhancing surgical outcomes worldwide. The impact of Dr. Caruso's work will be felt for generations.

Integra LifeSciences Holdings Corporation (IART) reported Q2 2022 revenues of $398 million, reflecting a 2.0% increase year-over-year. Adjusted earnings per diluted share reached $0.82, up from $0.79 in the previous year. The company has updated its full-year 2022 guidance, expecting revenues between $1,557 million and $1,575 million, amid divestiture plans for its non-core traditional wound care business. Strong performance in the Codman Specialty Surgical and Tissue Technologies segments was noted, along with cash flow from operations of $66 million.